Tools   Select Another Resource Report Type

https://www.urmc.rochester.edu/neurosurgery/specialties/neurooncology.aspx

Collaborative neuro-oncology research program with a tissue repository (tumor bank) containing a wide range of clinical specimens, which they make available to researchers in order to study the effects of new drugs on a large number and wide range of tumor specimens. They provide highly coordinated, complex care in neurosurgery, radiation oncology, medical oncology, and neurology to patients afflicted with tumors of the brain and spine by combining the newest technologies and treatments available anywhere in the world. The program is formed from a multidisciplinary group with a goal of helping patients navigate the complex issues surrounding brain and spinal cancer care. The researchers are working to increase the number of targets that could be considered for anti-angiogenesis therapy. Many of their studies focus on the blood vessel cells (endothelial cells) themselves, which, unlike tumor cells, rarely mutate and so might be less likely to become resistant to therapy and are also more easily reached through the bloodstream. Their researchers are also attempting to better understand the changes in the blood-brain barrier (BBB) that are associated with fluid accumulation and brain swelling (edema) in neuro-oncology patients. Normal brain tissue is shielded from the rest of the body by the BBB. This barrier is composed of very tight blood vessels that prevent most substances from entering the brain. Brain tumors have a leaky BBB ����?? this feature can be used to identify tumors on MRI scans. They have identified specific molecules that appear to be associated with the leaky, abnormal vessels while the normal blood vessels with intact BBB produce these molecules at very low levels or not at all. Inhibiting the function of these molecules may help control or prevent disruption of the BBB and limit cerebral edema in brain tumor patients, as well as patients suffering from stroke or traumatic brain injury.

Proper citation: University of Rochester Program for Brain Tumors and Spinal Tumors (RRID:SCR_005343) Copy   

•   Source: SciCrunch Registry

http://ucneuroscience.com/

Leading treatment, research and teaching center for complex neurological conditions based at the University Hospital and the UC College of Medicine. Its physicians and researchers have created national models for evidence-based treatment and research of complex conditions, including ischemic and hemorrhagic stroke, brain aneurysms, brain and spinal cord trauma, brain tumors, Parkinson's disease, epilepsy and seizure disorders, multiple sclerosis, trigeminal neuralgia, Alzheimer's disease and memory disorders, mood disorders, and neuromuscular disorders. UCNI includes a team of more than 100 experts from 15 specialties who collaborate across disciplines to provide the most comprehensive diagnoses and treatments possible.

Proper citation: University of Cincinnati Neuroscience Institute (RRID:SCR_005345) Copy   

•   Source: SciCrunch Registry

http://www.broadinstitute.org/science/programs/genome-biology/computational-rd/somaticcall-manual

Software program that finds single-base differences (substitutions) between sequence data from tumor and matched normal samples. It is designed to be highly stringent, so as to achieve a low false positive rate. It takes as input a BAM file for each sample, and produces as output a list of differences (somatic mutations). Note: This software package is no longer supported and information on this page is provided for archival purposes only.

Proper citation: SomaticCall (RRID:SCR_001196) Copy   

•   Source: SciCrunch Registry

http://www.oncotest.com/

A contract research organization (CRO) specializing in preclinical oncology services. As a pioneer in the field of patient derived tumor xenografts (PDX), they provide tailored solutions to the problems faced by preclinical oncology researchers. They assist with the identification of the best drug candidates and the validation of their targets and deliver in-depth bioinformatics analyses, laying the groundwork for the successful planning of clinical trials. Their diverse tumor model collection enables them to recommend the right assays and models to answer their customers' questions. Their AAALAC accredited facilities with IVC system, separate model development unit, large cage capacity of over 14,500 mice and proprietary electronic measurement system with an integrated database and by continuously maintaining important PDX models in mice, they are able to provide the highest standard of testing within a reasonable timeframe.

Proper citation: Oncotest (RRID:SCR_000489) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/variantmaster/

Software program that extracts causative variants in familial and sporadic genetic diseases. The algorithm takes into account predicted variants (SNPs and indels) in affected individuals or tumor samples and utilizes the row (BAM) data to robustly estimate the conditional probability of segregation in a family, as well as the probability of it being de novo or somatic. In familial cases, various modes of inheritance are considered: X-linked, autosomal dominant, and recessive (homozygosity or compound heterozygosity). Moreover, it integrates phenotypes and genotypes, and employs Annovar to produce additional information as allelic frequencies in general population and damaging scores.

Proper citation: VariantMaster (RRID:SCR_000569) Copy   

•   Source: SciCrunch Registry

http://patchwork.r-forge.r-project.org/

Software tool for analyzing and visualizing allele-specific copy numbers and loss-of-heterozygosity in cancer genomes. The data input is in the format of whole-genome sequencing data which enables characterization of genomic alterations ranging in size from point mutations to entire chromosomes. High quality results are obtained even if samples have low coverage, ~4x, low tumor cell content or are aneuploid. Patchwork takes BAM files as input whereas PatchworkCG takes input from CompleteGenomics files. TAPS performs the same analysis as Patchwork but for microarray data.

Proper citation: Patchwork (RRID:SCR_000072) Copy   

•   Source: SciCrunch Registry

http://hcc.musc.edu/research/resources/biorepository/

The Hollings Cancer Center Tissue Biorepository & Research Pathology Services Shared Resource provides investigators with a centralized infrastructure that promotes biomedical research involving the use and study of human biospecimens. The shared resource is comprised of four integrated components: Biospecimens and data bank, Laser Capture Microdissection, Tissue Microarray, and Research Pathology Services. These components, along with extensive staff expertise, offer a comprehensive means by which researchers can utilize valuable human biospecimens and cutting edge technology to support basic, translational and clinical research. Services: * Biospecimen and Data Bank ** Collecting, processing, and banking of tissue, saliva, urine, blood, plasma, serum, and other tissue derivatives; including those for protocol driven studies ** Retrieval of banked specimens linked to clinicopathologic data, while maintaining patient confidentiality, for research use ** Quality control of collected tissue by the Tissue Biorepository Director, a trained pathologist: verification of diseased state and assessment of tumor purity, etc ** Quality control of DNA/RNA/protein isolated from collected tissue using the Agilent Bioanalyzer * Laser Capture Microdissection ** Identification, localization, and microdissection of targeted cell populations (from human and animal tissue sources) ** Extraction of DNA/RNA/protein from microdissected samples. ** Quality analysis and quality control of isolated nucleic acid using Agilent Bioanalyzer * Tissue Microarray ** Create custom and standard TMAs ** Consultation and technical support in the construction and analyses of TMA * Research Pathology Services ** Macrodissection of tissue prior to isolation of DNA/RNA/protein to increase tumor purity ** Immunohistochemistry and In-situ hybridization ** Quantitative image analysis on conventional and TMA sections, including tissue scoring, Ki-67 labeling index, microvascular density counting, and tissue microarray scoring, etc. * Bio-molecular Assessment ** Cellular DNA, RNA and protein prepared by the Tissue Repository from banked specimens or any other biomolecules submitted by investigators can be qualitatively assessed by Agilent Bioanalyzer, prior to use for downstream applications such as microarray and/or qRT-PCR analysis

Proper citation: Hollings Cancer Center Tissue Biorepository and Research Pathology Services Shared Resource (RRID:SCR_004626) Copy   

•   Source: SciCrunch Registry

http://ercsb.ewha.ac.kr:8080/FusionGene/

Knowledgebase of fusion transcripts collected from various public resources such as the Sanger CGP, OMIM, PubMed, and Mitelman's database. It is an alignment viewer to facilitate examining reliability of fusion transcripts and inferring functional significance., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: ChimerDB (RRID:SCR_007596) Copy   

•   Source: SciCrunch Registry

http://neurosurgery.ucsf.edu/index.php/research_tissue_bank.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 4th,2023. Brain Tumor Research Center Tissue Bank began collecting tissue in 1978 and has established an organized repository of characterized tissues--frozen, paraffin-embedded, blood and cultures--that are maintained in a manner useful for a wide range of studies. Samples are collected only from patients who have agreed to have their tissues banked and used for future research. Consent documents are maintained in a secure area and associated clinical data are held in a double-password protected computer database. Each sample received into the Tissue Bank is non-identifying number. No protected health information (PHI) is released. To obtain samples, investigators submit a request form to the Manager. The request form requires an explanation of the tissue requested (type, number of samples, justification), description of the study, CHR approval (see new policy regarding human vs. non-human research) and Project Leader authorization. The Manager reviews each request for feasibility before presentation to the Scientific Core Committee. The UCSF Neurosurgery Tissue Bank makes its inventory of stock cell lines available to all investigators. Requested cells are grown in T-25 flasks and shipped FedEx Priority Overnight at the receipient's expense. However, if you prefer, we can ship the frozen cells, packed in dry ice. (Note: some countries restrict dry ice shipments.)

Proper citation: UCSF Brain Tumor Tissue Bank (RRID:SCR_000647) Copy   

•   Source: SciCrunch Registry

http://www.som.soton.ac.uk/research/sites/cruk/translation/tumour.asp

Collects and distributes human tissue for ethically approved studies to aid the study of cancer biology and other associated research. All tissue is collected with patient consent and tissue is distributed only to ethically approved studies. The purpose of the Tissue Bank is to source, organize, collect, prepare, store and distribute a diverse collection of human tissues and biological products. This valuable core resource is available to all local academics and researchers. The on-site bank allows for rapid access to a plethora of biological materials supported by an informatics system of databases acting as an inventory management system. In addition, the Tissue Bank provides a licensed facility to store surplus tissue when studies close. Tissues currently available include normal and malignant snap frozen blocks, freshly prepared spleen and lymph nodes, fresh biopsy tissues, blood products and biological fluids. Collections can be organized by bank staff or ran in parallel with current research activities and include a wide variety of cancer classifications. We currently hold over 38,000 vials. Tissue Availability: Lymphoma - solid tissue and cells - 843; Breast - solid tissue and cells - 540; Colon - solid tissue and cells - 238; Lung - solid tissue and cells - 43; Upper Gi - BIOPSY tissue - 114; Pleural fluid and cells - 14

Proper citation: Southampton Tumour Bank (RRID:SCR_000673) Copy   

•   Source: SciCrunch Registry

https://conticabase.sarcomabcb.org/

This database contains anonymized information describing the tumor, treatment and follow-up as well as tumor sample availability and molecular biology analyses for mesenchymal tumors except GIST and bone tumors. The query tool allows users to ask questions about the overall content of the database in order to evaluate the feasibility of specific collaborative studies. We hope this database will become an important tool for increasing our knowledge on these rare tumors and for developing joint research programs. The tool can be used as a local center database thanks to its rules for access to patient data and material. Conticabase currently contains the following data from 31 out of the 48 registered centers (Last modification on 28/03/2012): * 11518 Patients * 11562 Tumors * 13897 Samples (13636 Paraffin and 5773 Frozen) Use of conticabase data At anytime, a data manager can export data of patients from his (her) Centre or group according to his (her) level of rights. To obtain data from another Centre, a partner should ask the coordinator of the corresponding Centre for these data. To use data for a cooperative study, a member should write a short text describing the project and send it to partners of interest. Each partner may decide whether to participate or not and therefore, whether to send or not the corresponding data to the project leader. In the event that the data from the conticabase result in a publication, acknowledgement is required. Use of tumour material entered in the ConticaBank To obtain material from another Centre for a cooperative study, a partner should write a short text describing the project and send it to the partners of interest. Each partner may decide whether to participate or not and, therefore, whether to send or not the corresponding material to the project leader. In the event that the material used result in a publication, acknowledgement is required.

Proper citation: Conticabase - European Sarcoma Database and Tumour Bank (RRID:SCR_004832) Copy   

•   Source: SciCrunch Registry

http://www.erasmusmc.nl/pathologie/clinicalpathology/tissuebank/161255/?lang=en

The Erasmus MC Virtual Tissue Bank is embedded in the department of Pathology. The collection is meant for medical research purposes only. This concerns a typical clinical based pathology biobank. Tissue samples left over from surgical resection specimen are stored under liquid nitrogen and can be requested by Erasmus MC scientists for medical scientific experiments. An application has been developed to enable scientists to search the collection on-line and request tissue samples over the Erasmus MC Intranet. Every request shall be judged according to procedures determined by the Erasmus MC Tissue Bank. A growing need is anticipated for large collections of well-diagnosed fresh frozen tumor tissue and, if available, corresponding pre-malignant and normal tissue samples. Scientific research on patient residual material has to comply with strict rules and regulations. Equipment The Erasmus MC Tissue bank manages the PALM microdissection laser for the center for Biomics, which is available through the center for Biomics ONLY after having followed an introduction course. Additionally, a complete TMA (Tissue Micro Array) platform, fully funded by the Josephine Nefkens Stichting, consisting of a Beecher Automated Tissue Arrayer ATA 27 and a Virtual Microscope or Nanozoomer from Hamamatsu and Medical Solutions with TMA analyses software strongly supports translational research on tissue samples. Complete histologic Images from the Virtual Microscope are available within the Erasmus MC Intranet or available on the Internet either by overview or a direct example.

Proper citation: Erasmus MC Tissue Bank (RRID:SCR_004945) Copy   

•   Source: SciCrunch Registry

http://www.utmb.edu/scccb/htbc/htbc.htm

THIS RESOURCE IS NO LONGER IN SERVCE, documented September 2, 2016.

Proper citation: University of Texas Tumor Bank (RRID:SCR_005048) Copy   

•   Source: SciCrunch Registry

https://www.jax.org/jax-mice-and-services/in-vivo-pharmacology/mouse-tumor-biology-database

Database supports use of mouse model system for human cancer by providing comprehensive resource for data and information on various tumor models.

Proper citation: Mouse Tumor Biology Database (RRID:SCR_006517) Copy   

•   Source: SciCrunch Registry

http://epi.grants.cancer.gov/CFR/

The Breast Cancer Family Registry (Breast CFR) and the Colon Cancer Family Registry (Colon CFR) were established by the National Cancer Institute (NCI) as a unique resource for investigators to use in conducting studies on the genetics and molecular epidemiology of breast and colon cancer. Known collectively as the CFRs, they share a central goal: the translation of research to the clinical and prevention settings for the benefit of Registry participants and the general public. The CFRs are particularly interested in: * Identifying and characterizing cancer susceptibility genes; * Defining gene-gene and gene-environment interactions in cancer etiology; and * Exploring the translational, preventive, and behavioral implications of research findings. The CFRs do not provide funding for studies; however, researchers can apply to access CFR data and biospecimens contributed by thousands of families from across the spectrum of risk for these cancers and from population-based or relative controls. Special features of the CFRs include: * Population-based and clinic-based ascertainment; * Systematic collection of validated family history; * Epidemiologic risk factor , clinical, and followup data; * Biospecimens (including tumor blocks and Epstein-Barr virus (EBV)-transformed cell lines); * Ongoing molecular characterization of the participating families; and * A combined informatics center.

Proper citation: NCI Breast and Colon Cancer Family Registries (RRID:SCR_006664) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse1456/

Curated series of expression data for 159 tumors from which RNA could be collected in sufficient amounts and quality for analysis from breast cancer patients. Tissue material was collected from all breast cancer patients receiving surgery at Karolinska Hospital from 1994-1996.

Proper citation: GSE1456 (RRID:SCR_003642) Copy   

•   Source: SciCrunch Registry

http://www.stanford.edu/~rnusse/pathways/targets.html

A list of target genes of Wnt/beta-catenin signaling. Suggestions for additions are welcome. Direct targets are defined as those with Tcf binding sites and demonstrating that these sites are important.

Proper citation: Target genes of Wnt/beta-catenin signaling (RRID:SCR_007022) Copy   

•   Source: SciCrunch Registry

http://www.biobanks.se/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 6th, 2022. The biobank comprises paraffin blocks of surgical and autopsy tissue samples and corresponding histological slides as well as cytological material consisting of slides of vaginal smears, fine needle aspiration biopsies and exfoliative cytological material. The tissue samples date back until 1944 and most of the cytological samples until 1970. A subunit of the bank constitutes the National Tissue Microarray Centre. This center is supported by SWEGENE with the purpose to organize and construct tissue microarrays (TMA:s) for high throughput molecular pathology research on various kinds of tumors and other diseases. By linking the TMA.s to long-term and complete clinical follow-up data, prognostic and predictive studies will be facilitated. Biobank content: * Approximately 2,4 million paraffin blocks of surgical tissue specimens, * 1,1 million paraffin blocks of tissue samples from autopsies, * 3,8 million histological slides and * 1,6 million cytology slides. At present, the Tissue Microarray Centre includes: * A consecutive series of all invasive breast cancers (n=600) diagnosed in Malmo between 1988 and 1992. * All incident breast cancers within the Malmo Diet and Cancer cohort (n=400). * A subgroup of 600 pre-menopausal primary breast cancers within the nationwide, population-based randomized tamoxifen trial SBII:2. * 180 primary breast cancers from post-menopausal women included in a similar study. * A set of 120 extremely well characterized primary breast cancer samples with a clinical follow-up of 10 years. More than 40 relevant tumor biological parameters have been recorded in this material and it is therefore useful for a first screening of a marker in order to identify associations to other gene products. * 350 renal cell carcinomas (In collaboration with NUS). We provide researchers with state-of-the-art population based tissue microarrays with long-term and complete follow-up data on survival and treatment. With the TMA-technology, valuable biobank material will be preserved, allowing high throughput in-situ analyses of various tumors and other diseases with a minimal waste of tissue.

Proper citation: UMAS University Hospital - Biobanks of the Department of Clinical Pathology and Cytology (RRID:SCR_005957) Copy   

•   Source: SciCrunch Registry

http://www.chernobyltissuebank.com/

The CTB (Chernobyl Tissue Bank) is an international cooperation that collects, stores and disseminates biological samples from tumors and normal tissues from patients for whom the aetiology of their disease is known - exposure to radioiodine in childhood following the accident at the Chernobyl power plant. The main objective of this project is to provide a research resource for both ongoing and future studies of the health consequences of the Chernobyl accident. It seeks to maximize the amount of information obtained from small pieces of tumor by providing multiple aliquots of RNA and DNA extracted from well documented pathological specimens to a number of researchers world-wide and to conserve this valuable material for future generations of scientists. It exists to promote collaborative, rather than competitive, research on a limited biological resource. Tissue is collected to an approved standard operating procedure (SOP) and is snap frozen; the presence or absence of tumor is verified by frozen section. A representative paraffin block is also obtained for each case. Where appropriate, we also collect fresh and paraffin-embedded tissue from loco-regional metastases. Currently we do not issue tissue but provide extracted nucleic acid, paraffin sections and sections from tissue microarrays from this material. The project is coordinated from Imperial College, London and works with Institutes in the Russian Federation (the Medical Radiological Research Centre in Obninsk) and Ukraine (the Institute of Endocrinology and Metabolism in Kiev) to support local scientists and clinicians to manage and run a tissue bank for those patients who have developed thyroid tumors following exposure to radiation from the Chernobyl accident. Belarus was also initially included in the project, but is currently suspended for political reasons.

Proper citation: Chernobyl Tissue Bank (RRID:SCR_010662) Copy   

•   Source: SciCrunch Registry

http://cancergenome.nih.gov/

Project exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).

Proper citation: The Cancer Genome Atlas (RRID:SCR_003193) Copy   

•   Source: SciCrunch Registry